Pliant Therapeutics (NASDAQ:PLRX) Upgraded by Wall Street Zen to Hold Rating

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Sunday.

• Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

PLRX has been the subject of a number of other research reports. JPMorgan Chase & Co. reiterated an "underweight" rating on shares of Pliant Therapeutics in a research report on Friday, October 10th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Pliant Therapeutics in a research note on Wednesday, October 8th. Citigroup reiterated a "neutral" rating on shares of Pliant Therapeutics in a research note on Sunday, August 10th. Finally, Piper Sandler decreased their price target on Pliant Therapeutics from $17.00 to $4.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and a consensus price target of $3.93.

Check Out Our Latest Analysis on Pliant Therapeutics

Pliant Therapeutics Trading Down 2.3%

Shares of PLRX opened at $1.68 on Friday. The company has a current ratio of 13.94, a quick ratio of 12.99 and a debt-to-equity ratio of 0.15. The stock has a market cap of $103.23 million, a PE ratio of -0.58 and a beta of 1.41. Pliant Therapeutics has a 1 year low of $1.10 and a 1 year high of $15.80. The stock has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $1.51.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.10. On average, sell-side analysts predict that Pliant Therapeutics will post -3.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PLRX. Two Sigma Investments LP increased its stake in Pliant Therapeutics by 181.6% in the 3rd quarter. Two Sigma Investments LP now owns 783,255 shares of the company's stock valued at $1,159,000 after buying an additional 505,097 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Pliant Therapeutics by 17.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 182,356 shares of the company's stock valued at $270,000 after acquiring an additional 27,665 shares in the last quarter. Peapod Lane Capital LLC increased its position in shares of Pliant Therapeutics by 22.7% in the third quarter. Peapod Lane Capital LLC now owns 1,097,028 shares of the company's stock valued at $1,624,000 after acquiring an additional 203,298 shares during the last quarter. Monaco Asset Management SAM raised its holdings in Pliant Therapeutics by 17.1% during the third quarter. Monaco Asset Management SAM now owns 822,693 shares of the company's stock worth $1,218,000 after acquiring an additional 120,300 shares in the last quarter. Finally, GSA Capital Partners LLP raised its holdings in Pliant Therapeutics by 1,037.6% during the third quarter. GSA Capital Partners LLP now owns 160,884 shares of the company's stock worth $238,000 after acquiring an additional 146,742 shares in the last quarter. Institutional investors and hedge funds own 97.30% of the company's stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.

Featured Articles

• Five stocks we like better than Pliant Therapeutics
• What Are Treasury Bonds?
• Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?
• Short Selling - The Pros and Cons
• 3 Under-the-Radar AI Stocks to Buy on the Dip
• Insider Selling Explained: Can it Inform Your Investing Choices?
• Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pliant Therapeutics Right Now?

Before you consider Pliant Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pliant Therapeutics wasn't on the list.

While Pliant Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here